Clinical trial
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate…
NCT00170157 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00170157 |
|---|---|
| Title | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer |
| Official title | A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | Bicalutamide, Flutamide, Goserelin Acetate, Ipilimumab, Leuprolide Acetate, Pharmacological Study |
| Enrollment | 112 |
| Start date | Jun 1, 2004 |
| Primary completion | Apr 1, 2011 |
| Completion | Jun 1, 2013 |
| First posted | Sep 15, 2005 |
| Last update posted | May 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: